|
Hemato-oncology
Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia
Jang Ho Cho, Joon-Ho Shim, Sang Eun Yoon, Hee-Jin Kim, Sun-Hee Kim, Young Hyeh Ko, Seung-Tae Lee, Kihyun Kim, Won Seog Kim, Seok Jin Kim
Korean J Intern Med. 2021;36(3):668-678. Published online August 14, 2020
Background/Aims: Waldenström macroglobulinemia (WM) is a rare lymphoproliferative disorder that usually follows an indolent clinical course. However, some patients show an aggressive clinical course leading to death. We explored the risk factors predicting poor prognosis in WM patients.
Methods: ..
|
|
|
The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
Sung-Yong Kim, Sung Hwa Bae, Soo-Mee Bang, Ki-Seong Eom, Junshik Hong, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Min Kyoung Kim, Soo-Jeong Kim, Yeung-Chul Mun, Seung-Hyun Nam, Jinny Park, Jong-Ho Won, Chul Won Choi
Korean J Intern Med. 2021;36(1):45-62. Published online December 4, 2020
In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional som..
|
|
|
Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome
Hajeong Lee, Eunjeong Kang, Hee Gyung Kang, Young Hoon Kim, Jin Seok Kim, Hee-Jin Kim, Kyung Chul Moon, Tae Hyun Ban, Se Won Oh, Sang Kyung Jo, Heeyeon Cho, Bum Soon Choi, Junshik Hong, Hae Il Cheong, Doyeun Oh
Korean J Intern Med. 2020;35(1):25-40. Published online January 2, 2020
Thrombotic microangiopathy (TMA) is defined by specific clinical characteristics, including microangiopathic hemolytic anemia, thrombocytopenia, and pathologic evidence of endothelial cell damage, as well as the resulting ischemic end-organ injuries. A variety of clinical scenarios have features of ..
|
|
|
Hemato-oncology
Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea
Hae Su Kim, Hee-Jin Kim, Sun-Hee Kim, Joon Young Choi, Young Hyeh Ko, Won Seog Kim, Chul Won Jung, Seok Jin Kim
Korean J Intern Med. 2017;32(5):890-899. Published online August 18, 2017
Background/Aims: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that typically presents in the form of skin manifestations with or without lymph node and bone marrow involvement. Given its rarity and recent recognition as a distinct pathological entity, no stan..
|
|
|
Guidelines for the management of myeloproliferative neoplasms
Chul Won Choi, Soo-Mee Bang, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Soo-Jeong Kim, Yeo-Kyeoung Kim, Jinny Park, Jong-Ho Won
Korean J Intern Med. 2015;30(6):771-788. Published online October 30, 2015
Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysio..
|
|
|
Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience
A Young Lim, Ji Hyeon Lee, Ki Sun Jung, Hye Bin Gwag, Do Hee Kim, Seok Jin Kim, Ga Yeon Lee, Jung Sun Kim, Hee-Jin Kim, Soo-Youn Lee, Jung Eun Lee, Eun-Seok Jeon, Kihyun Kim
Korean J Intern Med. 2015;30(4):496-505. Published online June 29, 2015
Background/Aims: The gastrointestinal (GI) tract often becomes involved in patients with systemic amyloidosis. As few GI amyloidosis data have been reported, we describe the clinical features and outcomes of patients with pathologically proven GI amyloidosis.
Methods: We identified 155 patients dia..
|
|
|
